Phase 3 Clinical Trials With Primary Completion Dates in November 2017

This is a list of Phase 3 trials with primary completion dates in November 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AIMT Aimmune Therapeutics, Inc. 2017-11-01 Phase 3 NCT02635776 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
ALKS Alkermes plc 2017-11-01 Phase 3 NCT02696434 Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
ANTH Anthera Pharmaceuticals, Inc. 2017-11-01 Phase 3 NCT03051490 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
ATRC AtriCure, Inc. 2017-11-01 Phase 3 NCT02393885 Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach
FGEN FibroGen, Inc 2017-11-01 Phase 3 NCT01887600 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
JAZZ Jazz Pharmaceuticals plc 2017-11-01 Phase 3 NCT02221869 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
RDY Dr. Reddy's Laboratories Ltd 2017-11-01 Phase 3 NCT03290027 A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
RDY Dr. Reddy's Laboratories Ltd 2017-11-01 Phase 3 NCT03009019 Efficacy, Tolerability, and Safety of DFN-15
RDY Dr. Reddy's Laboratories Ltd 2017-11-01 Phase 3 NCT03006276 Efficacy, Tolerability, and Safety Study of DFN-15